MSD is paying $20 million upfront to activate an alliance with Flagship Pioneering's Quotient Therapeutics that will focus on finding new therapeutic targets in inflammatory bowel disease (IBD). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results